Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Accounts Payables (2018 - 2025)

Historic Accounts Payables for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $3.6 million.

  • Exagen's Accounts Payables rose 22208.14% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 22208.14%. This contributed to the annual value of $4.1 million for FY2024, which is 3213.03% up from last year.
  • As of Q3 2025, Exagen's Accounts Payables stood at $3.6 million, which was up 22208.14% from $2.5 million recorded in Q2 2025.
  • In the past 5 years, Exagen's Accounts Payables ranged from a high of $4.5 million in Q1 2025 and a low of $1.1 million during Q3 2024
  • Its 5-year average for Accounts Payables is $2.6 million, with a median of $2.5 million in 2021.
  • As far as peak fluctuations go, Exagen's Accounts Payables crashed by 5784.22% in 2023, and later surged by 22208.14% in 2025.
  • Over the past 5 years, Exagen's Accounts Payables (Quarter) stood at $2.5 million in 2021, then rose by 22.23% to $3.0 million in 2022, then increased by 2.79% to $3.1 million in 2023, then soared by 32.13% to $4.1 million in 2024, then fell by 13.97% to $3.6 million in 2025.
  • Its Accounts Payables was $3.6 million in Q3 2025, compared to $2.5 million in Q2 2025 and $4.5 million in Q1 2025.